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Abstract
GATA6 is a zinc finger transcription factor expressed in the colorectal epithelium. We have examined the expres-
sion of GATA6 in colon cancers and investigated the mechanisms by which GATA6 regulates colon cancer cell
invasion. GATA6 was overexpressed in colorectal polyps and primary and metastatic tumors. GATA6 was strongly
expressed in both the nuclear and cytoplasmic compartments of the colon cancer cells. GATA6 expression was
upregulated in invasive HT29 and KM12L4 cells compared with the parental HT29 and KM12 cells and positively
correlated with urokinase-type plasminogen activator (uPA) gene expression. Small interfering RNA (siRNA) knock-
down of GATA6 resulted in reduced uPA gene expression and cell invasion. GATA6 bound to the uPA gene regu-
latory sequences in vivo and activated uPA promoter activity in vitro. uPA promoter deletion analysis indicated that
the promoter proximal Sp1 sites were required for GATA6 activation of the uPA promoter. Accordingly, GATA6 phys-
ically associated with Sp1 and siRNA knockdown of Sp1 decreased GATA6 activation of the uPA promoter activity
suggesting that Sp1 recruits GATA6 to the uPA promoter and mediates GATA6 induced activation of the uPA pro-
moter activity. On the basis of our results, we conclude that GATA6 is an important regulator of uPA gene expres-
sion, and the dysregulated expression of GATA6 contributes to colorectal tumorigenesis and tumor invasion.
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Introduction
The GATA factors belong to an evolutionarily conserved family of
C2-type zinc finger proteins. There are six members of the vertebrate
GATA family. GATA1/2/3 are mainly expressed in the hematopoietic
lineages and GATA4/5/6 are expressed in endodermally derived tis-
sues, such as the gut, liver and lungs, and mesodermally derived tis-
sues, such as the heart [1]. In the adult small intestine, GATA4/5/6
are expressed in a partially overlapping pattern along the crypt-villus
axis [2,3]. GATA4/5/6 regulate various differentiation marker genes
expressed in gastrointestinal tissue by binding to the WGATAR se-
quences within the regulatory regions of these genes and interacting
with other ubiquitous and tissue-enriched transcriptional regulators
[2,4–7]. In addition to differentiation, GATA4/5/6 have been asso-
ciated with cell survival, cell proliferation, and neoplastic transforma-
tion of various cell types [8–15]. Among gastrointestinal cancers,
GATA4 is amplified in ∼10% of esophageal adenocarcinomas and
Barrett metaplasia [16]. The transition from normal esophageal epi-
thelium to Barrett metaplasia to adenocarcinoma is associated with
up-regulation of GATA6 [17]. Further, the GATA6 gene is amplified
in pancreatiobiliary cancers [12,18].
Colorectal cancer is the third most common cancer in the United
States. Although the localized primary colorectal tumors diagnosed
early can be effectively treated, the metastatic tumors that have
spread to different body parts are difficult to treat. The initial step
in metastasis is local invasion. This process involves changes in the
adherence and migratory properties of the primary cancer cells and
extensive degradation of the extracellular matrix surrounding the
primary tumor cells [19]. The urokinase-type plasminogen activa-
tor (uPA) system, which includes the serine protease (uPA), its recep-
tor (uPAR), and the endogenous inhibitors, plasminogen activator
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inhibitors 1 and 2, plays an important role in invasion and subsequent
metastasis of various tumors including colorectal tumors [20,21]. uPA
is expressed ubiquitously and is regulated both at the transcriptional
and posttranscriptional levels [22,23]. At the level of transcription,
uPA is regulated mainly by an enhancer located 2 kb upstream from
the transcription initiation site [24]. The activity of this enhancer re-
quires the cooperativity among the AP-1/PEA3 composite element, a
downstream AP1 site and regulatory factors that bind to cis-acting
sequences in between these two elements [25,26]. Transcriptional ac-
tivity of the uPA gene is highly dependent on the integrity of a GC/
GA–rich region located in the proximal promoter [22]. This region
binds Sp1 proteins [27]. In addition to directly activating uPA gene
expression, Sp1 also interacts with and recruits other transcription fac-
tors to the uPA promoter [28,29]. Apart from these ubiquitously ex-
pressed factors, several tissue-enriched factors, such as GATA6 and
RUNX/AML, target different regulatory elements of the uPA gene,
suggesting that the distinct promoter elements may be used in differ-
ent cell types to drive uPA gene expression [30,31].
Among the GATA family members, GATA5 and GATA6 are ex-
pressed in the adult colon [2,32]. Recent studies have demonstrated
that GATA5 is inactivated by promoter methylation and that it nega-
tively regulates colorectal cancer cell proliferation and invasion [33]. In
contrast, a strong expression of GATA6 in the proliferative crypt com-
partment of the intestine has suggested that GATA6 may be associated
with cellular proliferation. In support of this, GATA6 is strongly ex-
pressed in colon cancer–derived cell lines and upregulated in colon
cancers [34]. However, a recent study using a limited number of speci-
mens showed the up-regulation of GATA6 in benign lesions and sub-
sequent down-regulation in malignant lesions [35]. Because of these
contradictory reports, it is not clear whether GATA6 expression be-
comes dysregulated during the initial stages of development of colon
cancer such as dysplasia and polyposis or during subsequent stages of
malignant progression and metastasis. Understanding the temporal as-
pects of GATA6 dysregulation and the mechanisms by which GATA6
dysregulation contributes to colon carcinogenesis is important for early
diagnosis, determination of the course of treatment, and prognosis of
colon cancer. In this study, we show that the expression levels and the
localization of GATA6 protein is altered beginning from the earliest
stages of dysplasia continuing through the late metastatic lesions, sug-
gesting an important role for GATA6 in the initiation and progression
of colon cancer. While GATA6 was primarily nuclear in normal co-
lonic epithelium, GATA6 was strongly expressed in both the nuclear
and cytoplasmic compartments of the colon cancer cells. We have
identified uPA as a GATA6 target gene in colon cancer cells. GATA6
knockdown resulted in reduced uPA gene expression, colon cancer cell
migration, and invasion. We further show that GATA6 activates the
uPA promoter and physically interacts with Sp1 and Sp1, and the pro-
moter proximal Sp1 binding sites are required for GATA6-mediated
activation of the uPA gene expression.
Materials and Methods
Immunohistochemistry
Surgical samples containing primary tumors, adjacent normal tissues,
and metastatic tumors were collected in 10% buffered formalin accord-
ing to institutional review board–approved protocols and used in the
preparation of the customized tissue array. Deparaffinized sections
were boiled in TUF target unmasking solution (PanPath, Amsterdam,
the Netherlands), blocked in 5% horse serum, and incubated with
1:100 dilution of goat GATA6 antibody (R&D Systems, Minneapolis,
MN) or rabbit uPA antibody (American Diagnostica, Greenwich, CT)
overnight. Sections were processed using the VectaStain Elite kit (Vector
Laboratories, Burlingame, CA) and developed using 3-3′-diaminobenzi-
dine. Images were captured using Olympus BX51 microscope (Center
Valley, PA) equipped with CCD camera, and the images were processed
using Adobe Photoshop (San Jose, CA).
Recombinant DNA
Full-length uPA promoter-luciferase reporter was constructed by
cloning the 2.5-kb SmaI fragment containing the human uPA 5′ regu-
latory regions upstream of luciferase reporter in the pGL2 basic vector.
Promoter deletion constructs containing −2020, −1500, −510, −86,
and −30 bp of uPA promoter were constructed by cloning polymerase
chain reaction (PCR)–generated fragments in to pGL2 basic vector.
Deletion mutagenesis primer sequences are shown in Table W1. HA
epitope–tagged GATA6 expression vector was constructed by cloning
the PCR-generated rat GATA6 cDNA between the XbaI and BamHI
sites of the CMV promoter-enhancer–based pCGN vector.
Cell Culture and Transfections
HCT116 and HT29 cells were cultured in McCoy medium supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml
streptomycin, and 2 mM L-glutamine. KM12 and KM12L4 cells
were maintained in minimum essential medium supplemented with
10% fetal bovine serum, L-glutamine, sodium pyruvate, nonessential
amino acids, and vitamin solution (Invitrogen, Carlsbad, CA). HCT116
cells plated in 24-well plates were transfected in triplicates with 0.2 μg
of the uPA luciferase reporters along with 0.4 μg of GATA6 expres-
sion vector or pCGN empty vector. At 36 hours after transfections,
cells were harvested and analyzed for luciferase activity. For small in-
terfering RNA (siRNA) transfection experiments, 25, 50, and 100 nM
of GATA6 siRNA or a nonspecific control siRNA was transfected. To
assess the effect of GATA6 knockdown on uPA promoter-luciferase
activity, the 2.5-kb uPA promoter-luciferase reporter was cotransfected
with 100 nM of GATA6 or control siRNA. For Sp1 knockdown ex-
periments, Sp1 siRNA pool (Dharmacon/Thermo Fisher Scientific,
Lafayette, CO) was transfected into HCT116 using Dharnafect 1. Forty-
eight hours later, cells were transfected with the −520 uPA-luciferase
construct with GATA6 or pCGN empty vector.
Protein Extract Preparation and Western Blot Analysis
About 25 μg of protein extracts prepared from colon cancer cell
lines (HCT116, KM12, KM12L4, HT29, and invasive HT29) or
surgically removed tumors and adjacent normal tissues were resolved
on sodium dodecyl sulfate–10% polyacrylamide gels, transferred
to polyvinylidene fluoride membranes. The membranes were blocked
in tris-buffered saline–tween 20 containing 5% nonfat milk for
1 hour at room temperature and reacted with GATA6 and uPA anti-
bodies overnight at 4°C. The blots were probed with appropriate
HRP-conjugated secondary antibodies and developed using en-
hanced chemiluminescence.
Immunoprecipitation
Subconfluent HCT116 cells in 10-cm plates were transfected with
2 μg of HA epitope-tagged GATA6 and 4 μg of FLAG epitope-tagged
Sp1, either individually or together. pCDNA3 empty vector was used to
balance the total amount of transfected DNA to 6 μg. Cells were lysed
48 hours after transfection in lysis buffer (20 mM Tris-HCl pH 7.5,
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100 mM NaCl, 0.5% Nonidet P-40 containing EDTA-free HALT
protease inhibitor cocktail; Pierce Biotechnology, Rockford, IL), and
500 μg of cell lysates were immunoprecipitated with 15 λ of either
mouse HA or mouse FLAG antibody conjugated to red affinity gel
(Sigma, St Louis, MO) for 4 hours at 4°C. Immunoprecipitations
(IPs) were washed three times in IP buffer and analyzed byWestern blot
analysis with rabbit HA or FLAG antibodies.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation (ChIP) assays were performed
using the ChIP assay kit (Upstate/Millipore, Billerica, MA). GATA6-
and uPA-expressing colon cancer cell line, HCT 116, was used for
ChIP experiments. For ChIP assay, 2.5 μg of goat GATA6 antibody
(R&D Systems) or control nonimmune goat antibodies was used.
The ChIP products were analyzed by semiquantitative PCR using
primers spanning the 5′ flanking regulatory regions of uPA that
contained potential GATA binding sites. The primer sequences are
shown in Table W2.
In Vitro Invasion Assays
HCT116 cells plated in the Boyden chambers were transfected with
100 nM GATA6 siRNA (top strand 5′-CCAGGAAACGAAAAC-
CUAA-3′) or control siRNA (catalog no. 4611; Ambion/Applied Bio-
systems, Austin, TX) for 8 hours after which the medium was changed
with a fresh medium. At 48 hours after transfection, noninvading cells
within the chamber were removed with a sterile cotton swab, and the
cells that invaded the matrix and crossed over the membrane were
quantified colorimetrically using the invasion assay kit (Chemicon/
Millipore, Billerica, MA). More invasive HT29 cells were isolated based
on the differential ability of the nonclonal HT29 cells to invade and
successfully cross the cell matrix in Boyden chambers. Subcloning of
more invasive HT29 cells is explained in the Supplementary Informa-
tion section.
Statistical Analysis
Results were expressed as mean ± SD and analyzed for significance
with one-tailed Student’s t test.
Results
GATA6 Is Upregulated in Benign and Malignant Human
Colon Cancers
Recent studies have demonstrated that GATA6 is overexpressed in
a variety of cancers including colon cancers [12,18,34]. However,
precisely when during colorectal tumorigenesis GATA6 becomes
overexpressed and the potential mechanisms involved in GATA6
overexpression have not been addressed. In addition, it is not known
how GATA6 up-regulation contributes to the pathogenesis and pro-
gression of colorectal cancers. We have examined GATA6 protein
expression in 38 human polyps and a larger customized human colo-
rectal cancer tissue array consisting of 250 primary tumors, 208 spec-
imens of normal adjacent mucosa, and 89 metastatic tumors using
immunohistochemistry. In Western blot analysis of HCT116 cells
transfected with GATA4, GATA5, and GATA6, the goat GATA6 anti-
body reacted specifically with GATA6 but not GATA4 and GATA5
confirming the antibody specificity (data not shown). Specificity of
the immunostaining was confirmed by substituting the GATA6 anti-
body with nonimmune goat antibody (Figure 1, A and B). On the basis
of the relative intensity of staining, the immunostaining was graded on
a scale of +1 to +3, with +1 being the staining intensity detected in
normal colon, +2 being strong, and +3 being the strongest staining. In
normal colon, GATA6 was expressed within the nuclei of crypt epithe-
lial cells and, to a lesser extent, within the differentiated epithelial cells
at the top of the crypt (Figure 1, I and J , deep brown to black nuclear
stain indicated by white arrowheads in J ). Compared with the normal
crypts, GATA6 expression was increased in crypts showing the earliest
stages of dysplasia (Figure 1, C , D, E , and F, normal and dysplastic
regions indicated by white and red arrowheads, respectively). GATA6
was overexpressed in both tubular- and villous-type adenomas. GATA6
staining in 14% of adenomas was comparable to that of normal colon,
whereas majority of adenomas (86%) showed strong (+2) staining.
These data demonstrate that up-regulation of GATA6 seems to be a
very early event during colorectal tumorigenesis. Further up-regulation
of GATA6 was noted in carcinomas (Figure 1, K , L,M , and N ). Most
carcinomas (65%) showed strong staining (+2). Close to 25% of car-
cinomas stained strongest (+3), and only 10% showed staining com-
parable to normal colon. Interestingly, while GATA6 expression was
localized in the nuclei of normal mucosa and adenomas, adenocarci-
nomas showed strong nuclear and cytoplasmic GATA6 staining (Fig-
ure 1, K , L, M , and N ).
GATA6 Is Overexpressed in Metastatic Colorectal Cancers
Previously, it has been demonstrated that GATA6 and the related
GATA4 are targeted by small GTPase RhoA, a well-known regulator
of cytoskeletal remodeling and cell motility, and are implicated in
epithelial cell migration [36,37]. Therefore, we hypothesized that
the upregulated expression of GATA6 could be related to the invasive
phenotype of colon cancer cells. To investigate this hypothesis, we ex-
amined GATA6 protein expression in metastatic colon cancers. Strong
nuclear and cytoplasmic GATA6 expression was detected in colon can-
cer metastasis in lymph nodes, liver, and omentum (Figure 1, O, P, Q,
R, S , and T ). Hence, 42% of the metastatic carcinomas stained
strongly (+2) and 58% of the metastatic tumors stained the strongest
(+3). Although there seemed to be an increase in GATA6 expression
from adenoma to primary carcinoma to metastatic lesions, comparison
of GATA6 expression with the patient outcome indicated that GATA6
expression is not an independent prognostic marker of poor prognosis
(data not shown).
uPA Expression Is Upregulated in GATA6-Overexpressing
Colon Cancers
uPA is strongly upregulated in various malignancies including colo-
rectal cancers and serves as a prognostic marker. Previous studies have
shown that uPA up-regulation occurs in benign lesions (polyps) well
before transition to an invasive malignancy and subsequent metasta-
sis [38]. Because GATA6 is also upregulated starting from the earliest
stages of dysplasia, we hypothesized that the uPA expression may be
related to the dysregulated expression of GATA6 in polyps and colo-
rectal cancers. Immunostaining of successive sections of polyps dem-
onstrated precise overlapping of GATA6 and uPA staining in the
colonic epithelia, suggesting that GATA6 overexpression may be re-
lated to uPA expression during polyposis (Figure 1, E , F, G , and H ).
To examine whether GATA6 and uPA expressions are correlated in
adenocarcinomas, protein extracts prepared from three pairs of sur-
gically resected human colon cancers and the neighboring apparently
normal mucosa were probed with uPA and GATA6 antibodies. On
normalization to protein loading, both uPA and GATA6 levels were
strongly upregulated in tumor mucosa compared with the normal
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mucosa in all three pairs of specimens analyzed (Figure 2). An addi-
tional fast-migrating isoform of GATA6 of approximately 45 kDa
was enriched in colon cancer specimens.
GATA6 Expression Is Related to uPA Expression and
Colorectal Cancer Cell Invasion
To correlate GATA6 expression with colon cancer invasiveness, we
analyzed GATA6 protein levels in more invasive HT29 subclones.
HT29 colon cancer cell line is nonclonal and consists of a mixture
of cells, some of which are more invasive [39,40]. The more invasive
subclones were isolated based on their ability to rapidly invade and
cross the Matrigel-coated invasion chambers (unpublished observa-
tions). GATA6 protein was strongly upregulated in more invasive
subclones compared with the parental HT29 cells (Figure 3A). In
addition to cells selected for invasiveness in vitro, we examined
whether GATA6 was upregulated in colon cancer cells selected for in-
vasiveness in vivo. For this purpose, we chose KM12 and KM12L4
cells. Compared with KM12 cells, KM12L4 cells are highly invasive
and metastatic. KM12 cells were established from a primary human
colon cancer. KM12L4 cells were obtained by four repeated passages
of KM12 cells through the spleen of nude mice and selected for
increased metastasizing ability to liver [41]. GATA6 and uPA were
Figure 1. Immunohistochemical analysis of GATA6 expression in normal colon, polyps, primary adenocarcinomas, and metastatic tu-
mors. Sections of normal colon were stained with nonimmune goat antibody (A, B) or goat GATA6 antibody (I, J). In normal colon,
GATA6 was expressed within the nuclei of crypt epithelial cells and, to a lesser extent, within the differentiated epithelial cells at the
top of the crypt (deep brown to black nuclear stain indicated by white arrowheads in panel J). (C, D, E, and F) GATA6 staining in polyps.
White and red arrowheads in panel D indicate normal and dysplastic regions, respectively. uPA staining in a section adjacent to panels E
and F is shown in panels G and H. GATA6 staining in primary adenocarcinomas is shown in panels K, L, M, and N. Staining in metastatic
tumors from omentum (O, P), lymph node (Q, R), and liver (S, T). After immunostaining, sections were counterstained with hematoxylin.
Original magnification: (A, C, E, G, I, K, M, O, Q, S) ×100. Boxed areas from these images are shown at a magnification of ×400 in
panels B, D, F, H, J, L, N, P, R, and T, respectively.
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upregulated in KM12L4 cells compared with parental KM12 colon
carcinoma cells (Figure 3B).
GATA6 Is Required for uPA Gene Expression and
Cell Invasion
On the basis of the correlation between uPA production and
GATA6 overexpression in resected human colorectal tumors and
more invasive colon cancer cell lines, we examined whether GATA6
regulates uPA gene expression by knocking down GATA6 expression
in HCT116 colon cancer cells. HCT116 cells were selected for these
experiments because these cells are invasive and express high levels of
uPA. Compared with the control siRNA–transfected cells, GATA6
siRNA–transfected cells showed a dose-dependent down-regulation
of uPA protein expression, suggesting that GATA6 is a potential reg-
ulator of uPA gene expression (Figure 4A).
Figure 3. GATA6 expression is related to uPA expression and colo-
rectal cancer cell invasion. Protein extracts from parental HT29 and
more invasive HT29 clones (A) and less metastatic KM12 cells and
highly metastatic KM12L4 cells (B) were probed with uPA (top pan-
els) and GATA6 (middle panels) antibody. Stripped blots reprobed
with GAPDH internal control antibody are shown in the bottom pan-
els. Signals were quantified by densitometry. uPA and GATA6 sig-
nals normalized to the respective GAPDH loading control signals
are shown below the top and the middle panels.
Figure 2. uPA is upregulated in GATA6 overexpressing colorectal tumors. Protein extracts (25 μg) from paired cancerous (T) and adja-
cent mucosa (N) were analyzed by Western blot analysis with uPA antibody (top panel), GATA6 antibody (middle panel), and glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) antibody (bottom panel). Signals were quantified by densitometry. uPA and GATA6
signals normalized to the respective GAPDH loading control signals are shown below the top and the middle panels.
Figure 4. GATA6 is required for uPAexpression and coloncancer cell
invasion. (A) Protein extracts prepared from HCT116 colon cancer
cells transfected with increasing concentrations of control siRNA
(left panels) or GATA6 siRNA (right panels)were analyzedbyWestern
blot analysiswithGATA6 antibody (first panel), uPA antibody (second
panel), GATA4 antibody (third panel), and GAPDH antibody (fourth
panel). (B) HCT116 cells seeded in matrix-coated invasion chambers
were transfected with 100 nM control siRNA (column 1) or GATA6
siRNA (column 2). At 48 hours later, cells that invaded the matrix
and crossed the membrane were quantified colorimetrically. n = 3,
*P < .01 compared with control siRNA transfection.
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Because the expression of uPA, an important protease involved in
cancer cell invasion, depended on GATA6, we examined whether the
invasive phenotype of colon cancer cells is affected when GATA6 is
downregulated. HCT116 cells plated in matrix-coated invasion
chambers were transfected with GATA6 siRNA or control siRNA,
and the ability of transfected cells to invade the matrix and cross
the chamber was determined colorimetrically. Invasion by GATA6
siRNA–transfected cells was reduced by 50% compared with the
control siRNA–transfected cells, suggesting that GATA6 levels regu-
late the invasive phenotype of colon cancer cells (Figure 4B).
GATA6 Activates uPA Promoter Activity
uPA gene expression is known to be regulated by transcriptional,
posttranscriptional, and epigenetic mechanisms [22,23,42]. To deter-
mine whether GATA6 regulates uPA gene expression at the transcrip-
tional level, we cotransfected GATA6 siRNA or the control siRNA
along with a 2.5-kb uPA promoter-luciferase reporter into HCT116
cells. Compared with the control siRNA, GATA6 siRNA strongly
downregulated the uPA promoter activity, suggesting that GATA6
may regulate uPA gene expression at the transcriptional level (Fig-
ure 5A). A relatively lower decrease in luciferase activity with increas-
ing doses of control siRNA could be related to the often reported
nonspecific targeting or the toxicity associated with control siRNA.
To examine whether GATA6 activates the uPA promoter, we co-
transfected a 2.5-kb uPA-luciferase reporter along with the GATA6
expression vector or empty control vector into HCT116 cells. Ex-
pression of GATA6 but not the empty vector activated the uPA pro-
moter by five-fold (Figure 5B). To delineate the region(s) of the uPA
promoter that mediate(s) activation by GATA6, we used a series of
uPA promoter deletion mutants. Deletion of the promoter to −2020
slightly enhanced GATA6 mediated activation. A further deletion to
−520, which deletes the uPA enhancer, reduced the basal as well as
GATA6-induced activity by approximately 50%. These results sug-
gested that, although the uPA promoter sequences to −520 is suffi-
cient for GATA6 induced activation, sequences located between
−2020 and −520, which contains several consensus and nonconsen-
sus GATA-binding sites, are important for the maximal basal and
GATA6-induced activity of the uPA promoter.
GATA6 Activation of uPA Promoter Requires Sp1
A further deletion from −520 to −86 resulted in a slight increase in
GATA6 activation of the uPA promoter (Figure 6A). Although the
−520 promoter has potential nonconsensus GATA binding sites lo-
cated at −430 and −336, the −86 uPA promoter does not contain
discernible GATA binding sites. This construct contains five Sp1
binding sites spanning approximately 50 nucleotides, previously
shown to be essential for the activity of the uPA promoter [27]. De-
letion of all the Sp1 binding sites in the construct −30 completely
abolished GATA6-induced activation of the uPA promoter, suggest-
ing that GATA6 may target Sp1 family members to regulate uPA
Figure 5. GATA6 activates uPA gene expression. (A) HCT116 cells were transfected with the 2.5-kb uPA promoter-luciferase reporter
along with increasing concentrations of control siRNA or GATA6 siRNA. Luciferase values were read 36 hours after transfection. n = 3,
*P < .01 compared with control siRNA transfections. (B) HCT116 cells were transfected with the 2.5-kb uPA promoter-luciferase and
deletion mutants of uPA promoter-luciferase reporter constructs along with the GATA6 expression vector or pCGN empty vector. Dele-
tion constructs are diagrammatically shown on the left with numbers corresponding to nucleotide coordinates. Enh indicates enhancer;
Luc, luciferase; Sp1, Sp1 binding sites. n = 3, *P < .01, **P < .05.
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promoter activity (Figure 6A). Although both Sp1 and the related
family member, Sp3, can bind to these Sp1 binding sites in vitro,
only Sp1 but not Sp3 binds to these sites in vivo in uPA-producing
cells [27]. To investigate whether Sp1 is required for the GATA6-
activated uPA promoter activity, we used RNAi to knockdown Sp1
expression in HCT116 cells. GATA6 activation of the −520 uPA-
luciferase construct was significantly reduced in Sp1 siRNA–transfected
cells compared with the control siRNA–transfected cells (Figure 6B).
Together, these results suggest that GATA6 activation of the uPA
promoter is mediated by Sp1 and the Sp1 binding sites in the uPA
promoter proximal region.
GATA6 Binds to uPA Regulatory Regions In Vivo
Because endogenous uPA expression requires GATA6 and the uPA
promoter is activated by GATA6, we examined whether GATA6 binds
to the uPA promoter in vivo by ChIP analysis. Chromatin from uPA-
producing HCT116 cells was isolated and immunoprecipitated with
goat GATA6 antibody. A nonimmune goat antibody and acetylated
histone H3 antibodies were used as negative and positive controls, re-
spectively. The chromatin immunoprecipitates were analyzed by semi-
quantitative PCR with primers spanning −290 to −650 and −910 to
−1214 regions of uPA 5′ flanking region. These regions contain several
consensus and nonconsensus potential GATA6 binding sites. Results
of ChIP analysis indicated that GATA6 binds over the promoter prox-
imal −650 to −290 and promoter distal −1214 to −910 regions of the
uPA promoter (Figure 7, A and B). Because 86 bp of the promoter
Figure 6. Sp1 and Sp1 binding sites in the uPA promoter are re-
quired for GATA6 activation of the uPA promoter. (A) HCT116 cells
were transfected with the indicated uPA promoter deletion mu-
tants driving luciferase reporter along with the GATA6 expression
vector or pCGN empty vector. Deletion constructs are diagram-
matically shown on the left with numbers corresponding to nucle-
otide coordinates. Luc indicates luciferase; Sp1, Sp1 binding sites.
n = 3, *P < .01. (B) HCT116 cells were transfected with 100 nM
control siRNA or Sp1 siRNA. At 36 hours later, siRNA-transfected
cells were split into 24-well plates and transfected with −520 uPA
promoter luciferase or pGL2 basic promoter–enhancer less reporter
with GATA6 expression vector or pCGN empty vector. n = 3, **P <
.05. Protein lysates from control or Sp1 siRNA–transfected cells
were analyzed by Western blot analysis with Sp1 or internal stan-
dard actin antibodies, and a representative gel is shown in the inset.
Figure 7. (A-E) GATA6 binds to uPA regulatory regions in vivo.
Cross-linked chromatin from HCT116 cells was immunoprecipi-
tated with acetylated histone 3 antibody (lane 2), control nonim-
mune goat antibody (lane 3), and GATA6 antibody (lane 4) and
analyzed by PCR using the indicated uPA primers. The input con-
trol (5%) is in lane 1, and water control is in lane 5. Position of PCR
primers relative to the uPA cap site (arrow) and the polyadenyla-
tion signal (poly[A]) within the terminal exon 11 of the uPA gene
is shown diagrammatically in panel E. (F) GATA6 and Sp1 physically
interact. Five hundred micrograms of lysates from HCT116 cells
transfected with FLAG epitope–tagged Sp1 (lane 1), HA epitope–
tagged GATA6 (lane 2), or both (lane 3) was immunoprecipitated
with FLAG antibody and probed with HA antibody (third panel) or
immunoprecipitated with HA antibody and probed with FLAG anti-
body (bottom panel). Five percent of inputs were probed with HA
antibody (top panel) or FLAG antibody (second panel).
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region contained five Sp1 binding sites and no discernible GATA bind-
ing sites was sufficient for GATA6 activation of the uPA promoter,
we examined whether GATA6 can bind to this region of the uPA pro-
moter by analyzing the GATA6 ChIP using primers spanning −86 to
−30 regions of the uPA promoter. As shown in Figure 7C , this region
containing Sp1 binding sites and no discernible GATA sites was bound
by GATA6, albeit weakly, suggesting that GATA6 may bind to the
uPA promoter independent of GATA binding sites and by recruitment
through Sp1 binding sites. GATA6 recruitment was specific to the reg-
ulatory promoter region of uPA because a primer pair spanning the
nonregulatory exon 11 region of uPA (+6100 and +6540) was not am-
plified in GATA6 ChIP (Figure 7D).
GATA6 Physically Interacts with Sp1
The requirement for Sp1 protein and Sp1 binding sites in the
proximal promoter for GATA6 activation of uPA promoter suggested
that GATA6 may be recruited to the uPA promoter through physical
interaction between these two proteins. To examine this possibility, we
performed coimmunoprecipitation experiments in HCT116 cells by
transfecting FLAG epitope–tagged Sp1 or HA epitope–tagged GATA6
either alone or in combination. Sp1 protein was present in the im-
munoprecipitate of GATA6 only when coexpressed with GATA6
(Figure 7F, bottom panel ). Reciprocally, GATA6 was detected in the
immunoprecipitate of Sp1 on coexpression with Sp1, confirming that
Sp1 and GATA6 proteins physically interact with each other (Fig-
ure 7F, third panel ).
Discussion
Our results show that GATA6 is overexpressed in preneoplastic le-
sions and primary and metastatic colorectal tumors. Whereas dys-
regulated GATA6 expression in preneoplastic lesions suggests a role
for GATA6 in the earliest events that lead to colonic neoplasia, con-
tinued expression of GATA6 in primary and metastatic tumors sug-
gests a role for GATA6 in the progression of colon cancer. However,
the mechanisms by which overexpressed GATA6 participates in the ini-
tiation and/or progression of colorectal cancers is not known. GATA6
binding sites are present in the regulatory regions of members of the
wnt family of secreted glycoproteins such as wnt2, 4, 6, 7b, and 8b,
and GATA6 regulates the expression of wnt2, 7b, and 8 and the wnt
receptor Fzd2 [43–46]. Dysregulated expression of GATA6 in pre-
neoplastic colorectal lesions may lead to overexpression of target wnts,
which may trigger the wnt signaling pathway implicated in the patho-
genesis of colorectal cancers [47]. Continued overexpression of GATA6
in benign and malignant lesions may help in maintaining the activated
wnt–β-catenin signaling during progression of colorectal cancers. In
addition to wnts, GATA6 also regulates the expression of the members
of the transforming growth factor β family of proteins such as BMP4.
The BMP4 promoter contains consensus GATA binding sites, and
these sites are essential for GATA6-induced activation of the BMP4
promoter [48]. BMP4 is overexpressed in malignant and metastatic
colorectal cancers compared with benign lesions and normal mucosa
[49]. A recent genome-wide study has shown the association between
BMP4 and colorectal cancer [50]. BMP4 activates the Smad signaling
pathway and induces epithelial-mesenchymal transition and uPA pro-
duction in colorectal cancer cells and promotes cell migration and in-
vasion. In support of this, a recent study has shown that forced
expression of BMP4 in HCT116 colon cancer cells induces uPA gene
expression and enhanced cell migration and invasion [49]. GATA6 and
the related protein, GATA4, physically and functionally interact with
Smads and play an essential role in transforming growth factor β signal
transduction [4]. Thus, it is conceivable that the overexpression of
GATA6 will serve dual functions: leading to excessive production of
BMP4 and participating in the activation of BMP4-induced Smad
pathway signaling, leading to cell migration and invasion.
Although our studies have established a positive correlation be-
tween GATA6 overexpression and uPA gene expression using human
tumors and gain or loss of GATA6 function in colorectal cancer cell
lines, GATA6 may affect colon cancer cell migratory and invasive
properties independent of uPA. Other extracellular matrix degrading
proteases such as matrix metalloproteinases 2 and 9 are regulated by
GATA2 in endothelial cells [51]. Because all six members of the
GATA family bind to the same core GATA sequence, and GATA6
is the only member of this family expressed in colorectal cancers, the
expression of these matrix metalloproteinase in colorectal tumors may
be regulated by GATA6. GATA6 may also use pathways independent
of proteases to influence the cell migratory properties. GATA6 and
the related GATA4 proteins are targeted by small GTPase RhoA path-
way, an evolutionarily conserved pathway that regulates the migratory
behavior of normal and cancerous cells [36].
GATA6 is potentially both a tumor suppressor and a tumor pro-
moter. GATA6 activates the expression of tumor suppressor, Dab2,
and regulates the activity of LKB tumor suppressor protein [52,53].
Loss of GATA6 protein function either because of epigenetic silenc-
ing of GATA6 gene or GATA6 protein exclusion from the nuclei
has been reported in ovarian cancers [9,54]. Whereas GATA6 was
expressed in normal adrenal cortex, GATA6 expression was downreg-
ulated in adrenocortical tumors [15]. Further, GATA6 was downreg-
ulated in hyperplastic neointimal smooth muscle cells and forced
expression of GATA6 restored normoplasia [55]. A recent study has
revealed tumor suppressor activity of GATA6 in astrocytomas [10].
In contrast to the tumor-suppressing activity of GATA6 in these tis-
sues, GATA6 promotes tumorigenesis in the esophagus, pancreas, and
intestines [12,17,18,34,35]. Unlike ovarian cancers in which GATA6
is inactivated through nuclear exclusion, in aggressive colon adenocar-
cinomas, GATA6 staining is strongly cytoplasmic, suggesting a poten-
tial role for cytoplasmic GATA6 in promoting colon carcinogenesis.
Promoting uncontrolled cell proliferation and/or conferring resistance
to apoptosis are commonly used mechanisms by which oncoproteins
cause transformation. GATA6 does not seem to promote either. A re-
cent study by Shureiqi et al. [34] demonstrated that knockdown of
GATA6 in HCT116 colon cancer cells did not affect cell proliferation
and apoptosis. Thus, it is likely that GATA6 induces migratory and
invasive behavior by upregulating extracellular matrix–degrading pro-
teases, promoting invasion and metastasis, and confers survival advan-
tages in foreign microniches to establish secondary tumor foci.
GATA6 acts as both a transcriptional activator and a repressor de-
pending on the context of the regulatory regions of the target genes
and the cell type. GATA6 activates enteric epithelial-expressed genes,
such as lactase, and represses the expression of 15-lipoxygenase [56,57].
In addition, combinatorial interaction of GATA6 with various ubiqui-
tous and cell-type–enriched factors may determine whether GATA6
acts as an activator or a repressor. Although GATA6 is an activator
of uPA gene expression in colon cancer cells, GATA6 negatively regu-
lates uPA gene expression in endothelial cells by binding to the −692 to
−687 GATA binding site [31]. In HCT116 colon cancer cells, GATA6
binds to regions of uPA that contain multiple consensus and noncon-
sensus potential GATA sites located between −290 to −650 and −910
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to −1214. In addition, GATA6 activated the uPA promoter containing
Sp1 binding sites and bound to this region in vivo, although no dis-
cernible GATA binding sites were present within this region, suggest-
ing that GATA6 may be recruited to the uPA promoter by tethering to
DNA-bound Sp1. In support of this possibility, coimmunoprecipita-
tion experiments demonstrated a physical interaction between GATA6
and Sp1. Sp1 has been shown to recruit other transcription factors,
such as retinoic acid receptor α and retinoid X receptor α, to the
uPA promoter [29]. GATA6 physically and functionally interacts with
Sp1 to activate expression of various genes such as cytochrome p450c17
and aquaporin-5 [6,7]. Although cytochrome p450c17 promoter con-
tains consensus GATA binding sites that bind GATA6, GATA6 seems
to regulate this promoter primarily through the Sp1 binding sites, sug-
gesting that GATA6 can regulate gene expression both dependent and
independent of the GATA binding sites [6]. The promoter proximal
Sp1 sites are indispensable for uPA gene expression in uPA-producing
cancer cells, and binding of Sp1 to these Sp1 sites is highly dependent
on Sp1 phosphorylation [27,58]. It would be interesting to examine
whether GATA6 can both positively and negatively regulate uPA gene
expression in colorectal cancer cells by using distinct uPA promoter
elements and interacting with a distinct set of accessory factors and
if the transcriptional activating and repressing activities of GATA6
are impaired during colorectal carcinogenesis.
In conclusion, our results show that the dysregulated expression and
subcellular distribution of GATA6 occurs at the earliest stages of colo-
rectal tumorigenesis and continues through the later metastatic stages
and contributes to cell invasiveness by regulating the expression of the
uPA protease.
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Supplementary Information
Subcloning of More Invasive HT29 Cells
HT29 cells (1.0 × 105) were plated in matrix-coated 12-well Boyden
chamber inserts. After 48 hours of culturing, noninvading cells were
removed from the interior of inserts using sterile cotton swabs. Cells
that invaded the matrix and crossed over to the lower surface of the
membrane were recovered by treatment with trypsin and considered
as more invasive cells.
Table W1. List of Primers Used for Generating Deletion Mutants of uPA.
−2020 primer: 5′-TCCCCCGGGAGGGTGTCACGCTTCATAAC-3′
−1500 primer: 5′-TCCCCCGGGCTTCCTTCTGTCACTCTCAG-3′
−510 primer: 5′-TCCCCCGGGCTGAACAGACGCACAGAGGG-3′
−86 primer: 5′-TCCCCCGGGCGCTGCAAGACAGGGGAGGGA-3′
−30 primer: 5′-TCCCCCGGGTGATATAGAGCAGGCGCCGCG-3′
+34 primer: 5′-CCTCCCGGGCTCCGGGGCTGCGGTCTCCG-3′
Top strand sequence is shown for the −2020, −1500, −510, −86, and −30 primers. Bottom strand
sequence is shown for the +34 primer. SmaI site used for cloning of PCR products into SmaI site of
pGL2 basic vector is underlined.
Table W2. List of Primers Used for ChIP Analysis of uPA.
uPA ChIP −1214 (T) primer: 5′-GTCTGCTTATCCTCAGGCAG-3′
uPA ChIP −910 (B) primer: 5′-TCTGTTCTCACCTCTGAGTAG-3′
uPA ChIP −650 (T) primer: 5′-CCTTGCCTTTCCCCCTCTGA-3′
uPA ChIP −290 (B) primer: 5′-AGACTCTCTACCTCGCCCAG-3′
uPA ChIP −86 (T) primer: 5′-CGCTGCAAGACAGGGGAGGGA-3′
uPA ChIP −25 (B) primer: 5′-CAGGGCCCGCCCGGCGCCG-3′
uPA ChIP +6100 (T) primer: 5′-CCTCGTCTGTTCCCTCCAAGG-3′
uPA ChIP +6540 (B) primer: 5′-ACTCCTGCAGGCTTCAGTCCA-3′
Top strand (T) sequence is shown for the −1214, −650, −86, and +6100
forward primers. Bottom strand (B) sequence is shown for the −910,
−290, −25, and +6540 reverse primers.
